Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
FDF
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Alecensa
2. Alectinib
3. Ch5424802
4. Ro5424802
1. 1256589-74-8
2. Af-802 Hydrochloride
3. Alectinib Hcl
4. Alecensa
5. P9yy73lo6j
6. Alectinib Hydrochloride (jan)
7. Alectinib (hydrochloride)
8. Ch5424802 (hydrochloride)
9. Schembl14991271
10. 5h-benzo[b]carbazole-3-carbonitrile, 9-ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-, Hydrochloride (1:1)
11. Alectinib Hydrochloride [jan]
12. 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5h-benzo[b]carbazole-3-carbonitrile Hydrochloride
13. Unii-p9yy73lo6j
14. Alecensa (tn)
15. 5h-benzo(b)carbazole-3-carbonitrile, 9-ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-, Hydrochloride (1:1)
16. Alectinib Monohydrochloride
17. Af-802 (hydrochloride)
18. Agn-pc-09o9bf
19. Ro5424802 (hydrochloride)
20. Chembl3707320
21. Chebi:62268
22. Ch5424802 Hcl
23. Dtxsid10154841
24. Ch 5424802, Alectinib Hcl
25. Bcp09075
26. Ex-a1553
27. Alectinib Hydrochloride [mi]
28. Ch-5424802 Hydrochloride
29. Hy-13011a
30. Mfcd27987893
31. S5232
32. Ccg-264759
33. Cs-3480
34. Sb16516
35. Alectinib Hydrochloride [who-dd]
36. 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-ylpiperidin-1-yl)-11-oxo-5h-benzo[b]carbazole-3-carbonitrile,hydrochloride
37. Ac-29721
38. As-17062
39. Alectinib Hydrochloride [orange Book]
40. D10450
41. Q27104897
42. Ch5424802 Hcl Salt, Alectinib Hcl Salt, Af802 Hcl Salt
43. Ch-5428402 Hcl; Af-802 Hydrochloride; Rg-7853 Hydrochloride; Ro-5424802 Hydrochloride
44. 9-ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5h-benzo[b]carbazole-3-carbonitrile Hydrochloride (1:1)
45. 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5h-benzo[b]carbazole-3-carbonitrile Monohydrochloride Salt
46. 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-ylpiperidin-1-yl)-11-oxo-5h-benzo[b]carbazole-3-carbonitrile;hydrochloride
47. Alectinib Hydrochloride;af-802 Hydrochloride;ch-5424802 Hydrochloride;rg-7853 Hydrochloride;ro-5424802 Hydrochloride
1. Alectinib
2. 1256580-46-7
3. Arq-761
4. Cas 1416163-60-4
5. Cas 1256580-46-7
Molecular Weight | 519.1 g/mol |
---|---|
Molecular Formula | C30H35ClN4O2 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 3 |
Exact Mass | 518.2448541 g/mol |
Monoisotopic Mass | 518.2448541 g/mol |
Topological Polar Surface Area | 72.4 Ų |
Heavy Atom Count | 37 |
Formal Charge | 0 |
Complexity | 867 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Alecensa as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
Alecensa as monotherapy is indicated for the treatment of adult patients with ALKpositive advanced NSCLC previously treated with crizotinib.
L01ED03
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40093
Submission : 2024-06-13
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33869
Submission : 2019-06-12
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39383
Submission : 2024-01-30
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-07-19
Pay. Date : 2019-05-28
DMF Number : 33637
Submission : 2019-02-28
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2022-06-28
Pay. Date : 2022-03-15
DMF Number : 36908
Submission : 2022-03-25
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34128
Submission : 2019-12-16
Status : Active
Type : II
Date of Issue : 2022-09-30
Valid Till : 2025-09-15
Written Confirmation Number : WC-0115A3
Address of the Firm : D-35, Industrial Area, Kalyani, Dist Nadia-741 235, West Bengal
Date of Issue : 2022-09-02
Valid Till : 2025-05-05
Written Confirmation Number : WC-0349
Address of the Firm : MIs. MSN Laboratories Private Limited, Unit-II, sv. No, 50, Kardanur (Village), ...
NDC Package Code : 62128-0384
Start Marketing Date : 2015-12-11
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 50923-0117
Start Marketing Date : 2019-08-05
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 69988-0047
Start Marketing Date : 2013-09-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/1)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 68554-0150
Start Marketing Date : 2015-12-11
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 54893-0087
Start Marketing Date : 2019-02-28
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 72804-0002
Start Marketing Date : 2024-12-03
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
About the Company : Porton Pharma Solutions Ltd. was founded in 2005, & the company's stock was successfully listed in Shenzhen Stock Exchange in 2014. Our R&D, manufacturing & operation facilities ar...
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
About the Company : Egis is a member of the Servier Group. Egis’ products are manufactured at 3 production sites in Hungary, which are certified by EMA,FDA, ANVISA, PMDA ,KFDA. Egis sells its produc...
China's leading API and intermediate manufacturer, offering CMO/CDMO services and exports to 70+ countries, enhancing global health.
About the Company : Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. is specialized in R&D and production of APIs and advanced intermediates. With 22 years of production experience,the company has ...
Sichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..
About the Company : Specializing in natural & oncology APIs, we establish R&D and production platforms for new salt, crystal form & synthetic biology research. We cooperate with clients for IND, NDA, ...
About the Company : Cdymax (India) Pharma Private Limited was founded in 1994. The company's line of business includes the manufacturing, fabricating, or processing of drugs in pharmaceutical preparat...
About the Company : Divi's Laboratories Limited is a leading independent contract manufacturer of Active Pharmaceutical Ingredients and registered intermediates. We custom / exclusively manufacture fo...
About the Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and chemical products, cat...
About the Company : Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & F...
About the Company : Hunan Huateng Pharmaceutical Co., Ltd. is a research-based manufacturer and supplier of combinatorial building blocks, organics and fine chemicals, with 5000m2 laboratory and over ...
About the Company : NATCO PHARMA LIMITED was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million. With a modest beginning of operations as a single unit with 20 e...
RLD : Yes
TE Code :
Brand Name : ALECENSA
Dosage Form : CAPSULE;ORAL
Dosage Strength : EQ 150MG BASE
Approval Date : 2015-12-11
Application Number : 208434
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
Regulatory Info :
Registration Country : Switzerland
Brand Name : Alecensa
Dosage Form : Caps
Dosage Strength : 150mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Canada
ALECTINIB (ALECTINIB HYDROCHLORIDE)
Brand Name : ALECENSARO
Dosage Form : CAPSULE
Dosage Strength : 150MG
Packaging : 240
Approval Date :
Application Number : 2458136
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Australia
Brand Name : Alecensa
Dosage Form :
Dosage Strength :
Packaging : 224
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Related Excipient Companies
Excipients by Applications
Dosage Form : Capsule, Granule / Pellet, Tablet
Grade : Oral
Category : Coating Systems & Additives, Coloring Agents
Brand Name : Titanium dioxide PRETIOX AV01FG
Application : Coating Systems & Additives, Coloring Agents
Excipient Details : Titanium dioxide Pretiox AV01FG is used as a coloring and coating agent in oral solid dosage forms such as capsules, tablets, granules, and pellets.
Pharmacopoeia Ref : Fami-QS, Kosher, Halal, OHSAS ...
Technical Specs : Ti 59.95% and O 40.05%
Ingredient(s) : Titanium Dioxide
Dosage Form : Capsule, Granule / Pellet, Tablet
Grade : Oral
Category : Coating Systems & Additives, Coloring Agents
Dosage Form : Emulsion, Tablet
Grade : Oral, Ophthalmic
Category : Disintegrants & Superdisintegrants, Emulsifying Agents, Film Formers & Plasticizers, Thickeners and Stabilizers
Brand Name : Hydroxypropyl Methyl Cellulose
Application : Disintegrants & Superdisintegrants, Emulsifying Agents, Film Formers & Plasticizers, Thickeners and Stabilizers
Excipient Details : Hydroxypropyl Methyl Cellulose is used as a film-former, disintegrant, thickener, and emulsifier in tablets, emulsions, and ophthalmic formulations.
Grade : Not Available
Category : Coating Systems & Additives, Controlled & Modified Release
Application : Coating Systems & Additives, Controlled & Modified Release
Excipient Details : Film Forming Agent, Wet/Dry Granulation- Binder,Thickening & Suspension Agent, Non-Gelatin Capsule Manufacturing & Enteric Film Coating Systems
Pharmacopoeia Ref : USP, EP, and JP
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methylcellulose
Brand Name : Hydroxypropyl Methyl Cellulose
Application : Coating Systems & Additives
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methylcellulose
Grade : Not Available
Category : Coating Systems & Additives, Controlled & Modified Release
Application : Coating Systems & Additives, Controlled & Modified Release
Excipient Details : Sustained Release Tablet Matrix
Pharmacopoeia Ref : USP, EP, and JP
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methylcellulose
Dosage Form : Tablet
Grade : Not Available
Category : Coating Systems & Additives, Controlled & Modified Release
Application : Coating Systems & Additives, Controlled & Modified Release
Excipient Details : Immediate Release
Pharmacopoeia Ref : Customized per requirements
Technical Specs : Not Available
Ingredient(s) : Starch
Dosage Form : Tablet
Grade : Oral
Category : Coating Systems & Additives, Film Formers & Plasticizers
Application : Coating Systems & Additives, Film Formers & Plasticizers
Brand Name : Colorcoat MB4S(Clear)
Application : Coating Systems & Additives
Excipient Details : Transparent Coating
Global Sales Information
Dosage Form : Caps
Dosage Strength : 150mg
Price Per Pack (Euro) : 4978.12
Published in :
Country : Switzerland
RX/OTC/DISCN : Class A
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 902
2018 Revenue in Millions : 656
Growth (%) : 38
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 1,292
2019 Revenue in Millions : 976
Growth (%) : 32
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 1,459
2020 Revenue in Millions : 1,230
Growth (%) : 17
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 1,654
2021 Revenue in Millions : 1,459
Growth (%) : 13
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 1,743
2022 Revenue in Millions : 1,654
Growth (%) : -1
Main Therapeutic Indication : Oncology
Currency : USD
2017 Revenue in Millions : 384
2016 Revenue in Millions : 193
Growth (%) : 99
Main Therapeutic Indication : Oncology
Currency : USD
2018 Revenue in Millions : 643
2017 Revenue in Millions : 366
Growth (%) : 76%
Market Place
Reply
19 Dec 2024
Reply
05 Aug 2024
Reply
13 May 2022
Reply
07 Apr 2021
Reply
17 Jul 2018
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Alectinib Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Alectinib Hydrochloride, including repackagers and relabelers. The FDA regulates Alectinib Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Alectinib Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Alectinib Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Alectinib Hydrochloride supplier is an individual or a company that provides Alectinib Hydrochloride active pharmaceutical ingredient (API) or Alectinib Hydrochloride finished formulations upon request. The Alectinib Hydrochloride suppliers may include Alectinib Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Alectinib Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Alectinib Hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Alectinib Hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of Alectinib Hydrochloride DMFs exist exist since differing nations have different regulations, such as Alectinib Hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Alectinib Hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. Alectinib Hydrochloride USDMF includes data on Alectinib Hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Alectinib Hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Alectinib Hydrochloride suppliers with USDMF on PharmaCompass.
A Alectinib Hydrochloride written confirmation (Alectinib Hydrochloride WC) is an official document issued by a regulatory agency to a Alectinib Hydrochloride manufacturer, verifying that the manufacturing facility of a Alectinib Hydrochloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Alectinib Hydrochloride APIs or Alectinib Hydrochloride finished pharmaceutical products to another nation, regulatory agencies frequently require a Alectinib Hydrochloride WC (written confirmation) as part of the regulatory process.
click here to find a list of Alectinib Hydrochloride suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Alectinib Hydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Alectinib Hydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Alectinib Hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Alectinib Hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Alectinib Hydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Alectinib Hydrochloride suppliers with NDC on PharmaCompass.
Alectinib Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Alectinib Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Alectinib Hydrochloride GMP manufacturer or Alectinib Hydrochloride GMP API supplier for your needs.
A Alectinib Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Alectinib Hydrochloride's compliance with Alectinib Hydrochloride specifications and serves as a tool for batch-level quality control.
Alectinib Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Alectinib Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Alectinib Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Alectinib Hydrochloride EP), Alectinib Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Alectinib Hydrochloride USP).
LOOKING FOR A SUPPLIER?